28494325|t|HIV-1 integrase inhibitor resistance among treatment naïve patients in the West of Scotland
28494325|a|Transmitted integrase inhibitor resistance is rare, with only a small number of cases reported world-wide to date. The aim of this study was to assess whether transmitted integrase inhibitor resistance has occurred in Scotland and if so, could there be a case for performing genotypic integrase resistance testing at baseline. The study population consisted of 106 treatment naïve, newly diagnosed, HIV positive patients. The patient samples were collected between October 2015 and March 2016 at the time of HIV diagnosis and prior to initiation of anti-retroviral therapy. The integrase region was amplified and sequenced. We detected integrase inhibitor resistance (T66I/T) at baseline in one patient sample. This is a non-polymorphic mutation seen in patients receiving elvitegravir which confers high-level resistance to elvitegravir and intermediate resistance to raltegravir. A further 10 patients had accessory mutations which have minimal or no effect on susceptibility to integrase inhibitors. Transmitted integrase inhibitor resistance remains rare. The results of the present study do not support performing integrase resistance testing at baseline.
28494325	0	25	HIV-1 integrase inhibitor	T121	C2917373
28494325	26	36	resistance	T038	C0013203
28494325	43	52	treatment	T061	C0087111
28494325	59	67	patients	T101	C0030705
28494325	75	79	West	T082	C1705493
28494325	83	91	Scotland	T083	C0036453
28494325	92	103	Transmitted	T169	C0332289
28494325	104	123	integrase inhibitor	T121,T123	C0376601
28494325	124	134	resistance	T038	C0013203
28494325	138	142	rare	T080	C0522498
28494325	172	177	cases	T077	C1706256
28494325	178	186	reported	T170	C0684224
28494325	211	214	aim	T078	C1947946
28494325	223	228	study	T062	C2603343
28494325	236	242	assess	T052	C1516048
28494325	251	262	transmitted	T169	C0332289
28494325	263	282	integrase inhibitor	T121,T123	C0376601
28494325	283	293	resistance	T038	C0013203
28494325	310	318	Scotland	T083	C0036453
28494325	367	405	genotypic integrase resistance testing	T059	C0877124
28494325	409	417	baseline	T081	C1442488
28494325	423	439	study population	T098	C2348561
28494325	457	466	treatment	T061	C0087111
28494325	474	489	newly diagnosed	T080	C1518321
28494325	491	503	HIV positive	T034	C0019699
28494325	504	512	patients	T101	C0030705
28494325	518	533	patient samples	T031	C1550655
28494325	539	548	collected	T169	C1516698
28494325	600	613	HIV diagnosis	T060	C0920550
28494325	641	664	anti-retroviral therapy	T061	C1963724
28494325	670	686	integrase region	T028	C3534413
28494325	691	700	amplified	T045	C0017256
28494325	705	714	sequenced	T059	C1294197
28494325	719	727	detected	T033	C0442726
28494325	728	747	integrase inhibitor	T121,T123	C0376601
28494325	748	758	resistance	T038	C0013203
28494325	760	766	T66I/T	T045	C3534412
28494325	771	779	baseline	T081	C1442488
28494325	787	801	patient sample	T031	C1550655
28494325	813	837	non-polymorphic mutation	T045	C0026882
28494325	846	854	patients	T101	C0030705
28494325	865	877	elvitegravir	T109,T121	C2606637
28494325	892	902	high-level	T080	C0441889
28494325	903	913	resistance	T038	C0013203
28494325	917	929	elvitegravir	T109,T121	C2606637
28494325	934	946	intermediate	T082	C0205103
28494325	947	957	resistance	T038	C0013203
28494325	961	972	raltegravir	T114,T121	C1871526
28494325	987	995	patients	T101	C0030705
28494325	1000	1019	accessory mutations	T045	C0026882
28494325	1031	1038	minimal	T080	C0547040
28494325	1042	1051	no effect	T080	C1301751
28494325	1055	1069	susceptibility	T201	C0012655
28494325	1073	1093	integrase inhibitors	T121,T123	C0376601
28494325	1095	1106	Transmitted	T169	C0332289
28494325	1107	1126	integrase inhibitor	T121,T123	C0376601
28494325	1127	1137	resistance	T038	C0013203
28494325	1146	1150	rare	T080	C0522498
28494325	1156	1163	results	T033	C0683954
28494325	1179	1184	study	T062	C2603343
28494325	1211	1220	integrase	T121,T123	C0376601
28494325	1221	1231	resistance	T038	C0013203
28494325	1243	1251	baseline	T101	C0030705